Contact:

At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992

At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672

or
General Inquiries
Kathy Waller
312.640.6696

or
Media Inquiries
Tim Grace
312.640.6741

RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) (www.regenerx.com) announced that its President & CEO, J.J. Finkelstein, will be speaking at the Biotechnology Industry Organization’s (BIO) 2005 CEO & Investor Conference in New York on February 24th at 3:00 p.m. EST. The two-day conference features industry CEO’s discussing their companies’ technologies and business strategies. Attendees include pharmaceutical companies, wall street analysts, and members of the venture capital and investment banking communities. Mr. Finkelstein will be highlighting the company’s technology platform, clinical program, and provide an update on RegeneRx’s cardiac development strategy.

About RegeneRx Biopharmaceuticals, Inc.
RegeneRx (www.regenerx.com) is a biopharmaceutical company developing Thymosin beta 4 (Tß4) as a technology platform for the treatment of acute and chronic wounds and for a variety of human diseases involving tissue and organ repair under an exclusive world-wide license from the National Institutes of Health. In 2004, Tß4 was designated an “Orphan Drug” by the FDA for the treatment of patients with epidermolysis bullosa. The company’s intellectual property portfolio includes several issued patents and over fifty world-wide patent applications related to dermal, ocular, and internal wound and tissue repair, including the treatment/prevention of cardiac and neurological injuries. RegeneRx recently received clearance from the U.S. FDA for its first two Phase II dermal wound healing clinical trials.

Thymosin Beta 4
Tß4 is a naturally occurring peptide present in virtually all human cells. It represents a new class of wound healing drug and is different from other wound repair factors in that it has been shown to have numerous biological activities related to wound healing, including promotion of endothelial cell differentiation and keratinocyte cell migration and down-regulation of a number of inflammatory molecules. A key mechanism of action is Tß4’s ability to regulate the protein, actin, a vital structural component of cells that is necessary for cell movement. Recent scientific publications have shown that Tß4 directly influences the production of laminin-5, a protein required for proper adhesion of certain types of cells and an important component of the wound healing process. It has also been reported that Tß4 can inhibit or prevent apoptosis (programmed cell death) in ocular tissue and, possibly, cardiac tissue. Researchers at the National Institutes of Health, and other academic institutions, have published a number of articles indicating that Tß4 is effective in accelerating dermal and corneal wounds in several animal models, under a variety of conditions. Most recently, Tß4 was the subject of an article in the journal, Nature, indicating its ability to prevent and/or repair cardiac damage in laboratory animals after a myocardial infarction (heart attack).

Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development of Tß4 and possible future benefits to the Company, its stockholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2005 Press Release Archives